US Breast Cancer Therapy Market Opportunity Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Breast cancer is a type of malignancy that affects breast tissue and its incidences are increasing across the globe. It is also one of the most common cancers in American women which cause high morbidity and mortality rates. It affects both gender but most of the cases have been found to be related to females as compared to males. Data shows that the numbers of breast cancer incidences and death has remained stagnant with slight change in each year as compared to previous years. It also reflects that much change has not been observed despite use of better breast cancer therapeutics. So, it has become imperative to identify the solutions with which breast cancer could be treated effectively. Pharmaceutical companies are investing significantly in this segment to formulate effective strategy to prevent future breast cancer incidences.
Several breast cancer therapeutics have been introduced for providing higher safety and efficacy levels. These therapies belong to wide range of categories out of which some of them have achieved blockbuster status. Monoclonal antibodies (mAbs) are one of most widely used therapeutics owing to high safety, efficacy and specificity along with minimized side effects. Breast cancer market in US took a major leap when Genentech’s monoclonal antibody (mAb) Herceptin got FDA’s approval in 1998. Other big pharmaceutical companies soon followed the lead and introduced breast cancer monoclonal antibodies in US. Presently, the high cost of these medicines marketed makes it difficult for breast cancer patients to introduce them in their regular therapeutic regime. It is expected that in the near future, these companies will launch cost effective breast cancer medicines. Many pharmaceutical companies are also exploring the different areas for the development of efficient breast cancer therapeutics.
US Breast cancer market is dominated by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). The inhibition of HER2 is its basic mechanism to prevent the growth and proliferation of breast cancer in women. It was approved in 2012 by the FDA for the treatment of or late-stage metastatic HER2-positive breast cancer patients.
Various pharmaceutical companies are expected to introduce novel breast cancer medicines and technologies in future. Most of them are at different stages of clinical trials and would be introduced in coming years. However, the cost of pharmacologically superior therapeutics is quite high due to which limited breast cancer patients include them in their therapeutic regime. In future, the high cost breast cancer medicines will be replaced by affordable medicines due to advancements in technologies. Nanotechnology based breast cancer medicines are being developed whose introduction in US may take time. New molecular targets are also being investigated that would help in development of innovative medicines in coming years. These developments shows that US breast cancer market will increase as new products would be introduced. In this way, future of breast cancer therapeutics in US seems to be optimistic.
'US Breast Cancer Therapy Market Opportunity Analysis' Report Highlight:
Breast cancer is a type of malignancy that affects breast tissue and its incidences are increasing across the globe. It is also one of the most common cancers in American women which cause high morbidity and mortality rates. It affects both gender but most of the cases have been found to be related to females as compared to males. Data shows that the numbers of breast cancer incidences and death has remained stagnant with slight change in each year as compared to previous years. It also reflects that much change has not been observed despite use of better breast cancer therapeutics. So, it has become imperative to identify the solutions with which breast cancer could be treated effectively. Pharmaceutical companies are investing significantly in this segment to formulate effective strategy to prevent future breast cancer incidences.
Several breast cancer therapeutics have been introduced for providing higher safety and efficacy levels. These therapies belong to wide range of categories out of which some of them have achieved blockbuster status. Monoclonal antibodies (mAbs) are one of most widely used therapeutics owing to high safety, efficacy and specificity along with minimized side effects. Breast cancer market in US took a major leap when Genentech’s monoclonal antibody (mAb) Herceptin got FDA’s approval in 1998. Other big pharmaceutical companies soon followed the lead and introduced breast cancer monoclonal antibodies in US. Presently, the high cost of these medicines marketed makes it difficult for breast cancer patients to introduce them in their regular therapeutic regime. It is expected that in the near future, these companies will launch cost effective breast cancer medicines. Many pharmaceutical companies are also exploring the different areas for the development of efficient breast cancer therapeutics.
US Breast cancer market is dominated by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). The inhibition of HER2 is its basic mechanism to prevent the growth and proliferation of breast cancer in women. It was approved in 2012 by the FDA for the treatment of or late-stage metastatic HER2-positive breast cancer patients.
Various pharmaceutical companies are expected to introduce novel breast cancer medicines and technologies in future. Most of them are at different stages of clinical trials and would be introduced in coming years. However, the cost of pharmacologically superior therapeutics is quite high due to which limited breast cancer patients include them in their therapeutic regime. In future, the high cost breast cancer medicines will be replaced by affordable medicines due to advancements in technologies. Nanotechnology based breast cancer medicines are being developed whose introduction in US may take time. New molecular targets are also being investigated that would help in development of innovative medicines in coming years. These developments shows that US breast cancer market will increase as new products would be introduced. In this way, future of breast cancer therapeutics in US seems to be optimistic.
'US Breast Cancer Therapy Market Opportunity Analysis' Report Highlight:
- US Breast Cancer Incidence & Prevalence
- US Breast Cancer Therapy Market Overview
- US Breast Cancer Drug Clinical Pipeline by Company & Phase
- US Breast Cancer Drug Clinical Pipeline: 251 Drugs
- Majority Drugs in Phase-II Trials: 73 Drugs
- Marketed Breast Cancer Drugs in US: 32 Drugs
- Breast Cancer Patent Analysis
1. US BREAST CANCER INCIDENCE & PREVALENCE
2. US BREAST CANCER THERAPY MARKET OVERVIEW
2.1 Current Market Scenario
2.2 US Breast Cancer Drug Pipeline Overview
3. US BREAST CANCER THERAPY MARKET DYNAMICS
3.1 Favorable Market Parameters
3.2 Commercialization Challenges
4. US BREAST CANCER THERAPY MARKET FUTURE PROSPECTS
5. MECHANISM OF BREAST CANCER DRUGS
6. US BREAST CANCER DRUG CLINICAL PIPELINE BY COMPANY & PHASE
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-0
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered
7. MARKETED BREAST CANCER DRUG CLINICAL INSIGHT & PATENT ANALYSIS BY COMPANY IN US
7.1 Albumin-Bound Paclitaxel (Abraxane)
7.2 Anastrozole (Arimidex)
7.3 Capecitabine (Xeloda)
7.4 Docetaxel (Taxotere)
7.5 Eribulin (Halaven)
7.6 Everolimus (Afinitor)
7.7 Exemestane (Aromasin)
7.8 Fluoxymesterone
7.9 Fulvestrant (Faslodex)
7.10 Gadobutrol
7.11 Gemcitabine (Gemzar)
7.12 Goserelin (Zoladex)
7.13 Ixabepilone (Ixempra)
7.14 Lapatinib (Tykerb)
7.15 Letrozole (Femara)
7.16 Paclitaxel (Taxol)
7.17 Palbociclib (Ibrance)
7.18 Pertuzumab (Omnitarg)
7.19 Pertuzumab Companion Diagnostic (HER2 FISH pharmDx)
7.20 Pertuzumab Companion Diagnostic (HercepTest)
7.21 Raloxifene (Evista)
7.22 Tamoxifen Oral Liquid (Soltamox)
7.23 Tc 99m Tilmanocept (Lymphoseek)
7.24 Technetium Tc 99m Sulfur Colloid Diagnostic Injection
7.25 Temsirolimus (Fareston)
7.26 Trastuzumab (Herceptin)
7.27 Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)
7.28 Trastuzumab Companion Diagnostic (HER2 FISH pharmDx)
7.29 Trastuzumab Companion Diagnostic (HercepTest)
7.30 Trastuzumab Emtansine (Kadcyla)
7.31 Vinorelbine
7.32 Vitamin B12 Fluorescent-Analogues (CobalaFluor Green, CobalaFluor Red)
8. DISCONTINUED & SUSPENDED BREAST CANCER DRUG IN CLINICAL PIPELINE IN US
8.1 No Development Reported
8.2 Discontinued
8.3 Preregistration-Submission Withdrawal
8.4 Suspended
9. COMPETITIVE LANDSCAPE
9.1 AbbVie
9.2 Agilent Technologies
9.3 ARIAD Pharmaceuticals
9.4 AstraZeneca
9.5 Bayer
9.6 Biodesix
9.7 BioMarin Pharmaceutical
9.8 Boehringer Ingelheim
9.9 Bristol Mayer Squibb
9.10 Celgene Corporation
9.11 Dako A/S
9.12 Debiopharm
9.13 Dyax
9.14 Eisai
9.15 Eli Lily
9.16 Exelixis
9.17 GalaxoSmithKline
9.18 Incyte Corporation
9.19 Ligand Pharmaceuticals
9.20 Merck
9.21 Navidea Biopharmaceuticals
9.22 Nektar Therapeutics
9.23 Novartis
9.24 Onyx pharmaceuticals
9.25 Pfizer
9.26 Roche
9.27 Sanofi
9.28 Sun Pharmaceuticals
2. US BREAST CANCER THERAPY MARKET OVERVIEW
2.1 Current Market Scenario
2.2 US Breast Cancer Drug Pipeline Overview
3. US BREAST CANCER THERAPY MARKET DYNAMICS
3.1 Favorable Market Parameters
3.2 Commercialization Challenges
4. US BREAST CANCER THERAPY MARKET FUTURE PROSPECTS
5. MECHANISM OF BREAST CANCER DRUGS
6. US BREAST CANCER DRUG CLINICAL PIPELINE BY COMPANY & PHASE
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-0
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered
7. MARKETED BREAST CANCER DRUG CLINICAL INSIGHT & PATENT ANALYSIS BY COMPANY IN US
7.1 Albumin-Bound Paclitaxel (Abraxane)
7.2 Anastrozole (Arimidex)
7.3 Capecitabine (Xeloda)
7.4 Docetaxel (Taxotere)
7.5 Eribulin (Halaven)
7.6 Everolimus (Afinitor)
7.7 Exemestane (Aromasin)
7.8 Fluoxymesterone
7.9 Fulvestrant (Faslodex)
7.10 Gadobutrol
7.11 Gemcitabine (Gemzar)
7.12 Goserelin (Zoladex)
7.13 Ixabepilone (Ixempra)
7.14 Lapatinib (Tykerb)
7.15 Letrozole (Femara)
7.16 Paclitaxel (Taxol)
7.17 Palbociclib (Ibrance)
7.18 Pertuzumab (Omnitarg)
7.19 Pertuzumab Companion Diagnostic (HER2 FISH pharmDx)
7.20 Pertuzumab Companion Diagnostic (HercepTest)
7.21 Raloxifene (Evista)
7.22 Tamoxifen Oral Liquid (Soltamox)
7.23 Tc 99m Tilmanocept (Lymphoseek)
7.24 Technetium Tc 99m Sulfur Colloid Diagnostic Injection
7.25 Temsirolimus (Fareston)
7.26 Trastuzumab (Herceptin)
7.27 Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)
7.28 Trastuzumab Companion Diagnostic (HER2 FISH pharmDx)
7.29 Trastuzumab Companion Diagnostic (HercepTest)
7.30 Trastuzumab Emtansine (Kadcyla)
7.31 Vinorelbine
7.32 Vitamin B12 Fluorescent-Analogues (CobalaFluor Green, CobalaFluor Red)
8. DISCONTINUED & SUSPENDED BREAST CANCER DRUG IN CLINICAL PIPELINE IN US
8.1 No Development Reported
8.2 Discontinued
8.3 Preregistration-Submission Withdrawal
8.4 Suspended
9. COMPETITIVE LANDSCAPE
9.1 AbbVie
9.2 Agilent Technologies
9.3 ARIAD Pharmaceuticals
9.4 AstraZeneca
9.5 Bayer
9.6 Biodesix
9.7 BioMarin Pharmaceutical
9.8 Boehringer Ingelheim
9.9 Bristol Mayer Squibb
9.10 Celgene Corporation
9.11 Dako A/S
9.12 Debiopharm
9.13 Dyax
9.14 Eisai
9.15 Eli Lily
9.16 Exelixis
9.17 GalaxoSmithKline
9.18 Incyte Corporation
9.19 Ligand Pharmaceuticals
9.20 Merck
9.21 Navidea Biopharmaceuticals
9.22 Nektar Therapeutics
9.23 Novartis
9.24 Onyx pharmaceuticals
9.25 Pfizer
9.26 Roche
9.27 Sanofi
9.28 Sun Pharmaceuticals
LIST OF FIGURES
Figure 1-1: US -Estimated Breast Cancer Incidences, 2013-2015
Figure 1-2: US - Estimated Breast Cancer Deaths, 2013-2015
Figure 1-3: US -Estimated Incidences of Female Breast Cancer, 2013-2015
Figure 1-4: US -Estimated Female Breast Cancer Deaths, 2013-2015
Figure 1-5: US -Female Breast Cancer Incidence Compare to Others Cancers, 2015
Figure 1-6: US -Female Breast Cancer Deaths as compared to other Cancers, 2015
Figure 1-7: Diagnosis of Breast Cancer in Different Genders
Figure 1-8: US -Estimated Male Breast Cancer New Cases, 2013-2015
Figure 1-9: US -Estimate Male Breast Cancer Deaths, 2013-2015
Figure 2-1: US - Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-2: US -Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 2-3: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-4: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 2-5: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-6: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 2-7: US - Suspended Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-8: US -Suspended Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 3-1: US Breast Cancer Market Drivers
Figure 3-2: US Breast Cancer Therapy Market Commercialization Challenges
Figure 5-1: Type of Breast Cancer Treatment
Figure 5-2: Type of Breast Cancer Surgery
Figure 5-3: Mechanism of Trastuzumab
Figure 5-4: Mechanism of Docetaxel
Figure 5-5: Mechanism of Tamoxifen
Figure 9-1: AbbVie-Clinical Pipeline
Figure 9-2: ARIAD-Clinical Pipeline
Figure 9-3: Celgene Clinical Pipeline
Figure 9-4: Debiopharm-Clinical Pipeline
Figure 9-5: Eisai-Clinical Pipeline
Figure 1-1: US -Estimated Breast Cancer Incidences, 2013-2015
Figure 1-2: US - Estimated Breast Cancer Deaths, 2013-2015
Figure 1-3: US -Estimated Incidences of Female Breast Cancer, 2013-2015
Figure 1-4: US -Estimated Female Breast Cancer Deaths, 2013-2015
Figure 1-5: US -Female Breast Cancer Incidence Compare to Others Cancers, 2015
Figure 1-6: US -Female Breast Cancer Deaths as compared to other Cancers, 2015
Figure 1-7: Diagnosis of Breast Cancer in Different Genders
Figure 1-8: US -Estimated Male Breast Cancer New Cases, 2013-2015
Figure 1-9: US -Estimate Male Breast Cancer Deaths, 2013-2015
Figure 2-1: US - Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-2: US -Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 2-3: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-4: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 2-5: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-6: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 2-7: US - Suspended Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-8: US -Suspended Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 3-1: US Breast Cancer Market Drivers
Figure 3-2: US Breast Cancer Therapy Market Commercialization Challenges
Figure 5-1: Type of Breast Cancer Treatment
Figure 5-2: Type of Breast Cancer Surgery
Figure 5-3: Mechanism of Trastuzumab
Figure 5-4: Mechanism of Docetaxel
Figure 5-5: Mechanism of Tamoxifen
Figure 9-1: AbbVie-Clinical Pipeline
Figure 9-2: ARIAD-Clinical Pipeline
Figure 9-3: Celgene Clinical Pipeline
Figure 9-4: Debiopharm-Clinical Pipeline
Figure 9-5: Eisai-Clinical Pipeline
LIST OF TABLES
Table 1-1: US -Estimated Number of New Cases for Female Breast Cancer by State, 2015
Table 1-2: US -Estimated Number of Deaths for Breast Cancer by State, 2015
Table 1-1: US -Estimated Number of New Cases for Female Breast Cancer by State, 2015
Table 1-2: US -Estimated Number of Deaths for Breast Cancer by State, 2015
